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BOOK REVIEW
Statistical Issues in Drug Development, 2nd ed., by S. Senn, New York: Wiley, 2007,
ISBN 978-0-470-01877-4, xix + 498 pp., $130.
I suspect that Dr. Senn is a hero to many readers of this journal. He has been a
fervent advocate of the quality of work done by pharmaceutical statisticians in a day
and age where many dismiss any research touched by commercial interests (Senn,
2005, 2006). He also argues loud and forcefully for patients when their lives are
trampled by unethical demands of the research enterprise (Senn, 1997, 2003a). He
has written the deﬁnitive work on crossover trials (Senn, 2002), and a wonderfully
readable account of statistics in medicine for the lay public (Senn, 2003b). He is
the source of untold delightful quotes. My favorite is his deﬁnition of medical
statistician: “one who will not accept that Columbus discovered America    because
he said he was looking for India in the trial plan.” Finally, he is an all-around smart
guy who has moved the statistics discipline forward in many different areas. Dr.
Senn is one of the few people whose books you would be well advised to buy based
on his reputation alone.
The second edition of Statistical Issues in Drug Development updates a book
originally published in 1997 and it maintains much of the same organization. Dr.
Senn has provided word counts for each chapter in the ﬁrst and second edition.
The average chapter has increased by about 2,000 words, with most of the increases
occurring in the second half of the book.
The ﬁrst ﬁve chapters of Statistical Issues in Drug Development offer a very
general perspective, including a nice historical overview. The discussion of the
proper role of a statistician in a pharmaceutical company will help others to
appreciate the depth and breadth of our contributions, but Dr. Senn also holds us
to a very high standard. I was humbled, for example, by a discussion on page 58 of
how a statistician familiar with pulmonary function testing might be well-positioned
to discuss the implications on design and sample size when peak expiratory ﬂow is
substituted for forced expiratory volume. I’ve worked with such measures for more
than two decades, but I doubt that I have sufﬁcient medical appreciation of these
tests to discuss this topic at the level suggested here.
The remaining 20 chapters of the book cover speciﬁc topics such as baseline
adjustments, subgroup analysis, multiplicity, intention-to-treat analysis, multicenter
trials, equivalence studies, meta-analysis, cross-over trials, n-of-1 trials, sequential
trials, dose-ﬁnding, pharmacokinetics/dynamics, pharmacoepidemiology, and
pharmacoeconomics. A new chapter in the second edition covers pharmacogenetics.
Discussion of the controversy between frequentists and Bayesians is
distributed through many different chapters of this book. Dr. Senn has a
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dispassionate discussion of these and other issues, which is a rare and welcome
change. When Dr. Senn does not like a commonly used approach, he ﬁnds a way
to disagree without being disagreeable.
Dr. Senn leaves almost no stone uncovered. There is no discussion of medical
devices, but this cannot be considered an omission in a book with the words “drug
development” in the title. I do worry about Dr. Senn’s failure to mention any special
issues related to pediatrics. Regulators are increasingly mandating special testing
to allow appropriate dosing information for children (Hampton, 2004), and these
studies raise special challenges for everyone, including the statisticians. In general,
the book provides an excellent coverage to such a broad and diverse area.
One needs to be careful in describing the audience for a book like this. A
practicing statistician will ﬁnd that this book does not cover any particular topic in
the level of detail that such a person needs. You won’t be able to properly design
and analyze a group sequential trial, for example, after reading the chapter on this
topic. What this book provides is a gentle introduction to an area, an outline of
the major controversies in that area, and references for anyone who wants to dig
further. If you are moving into an area of drug development that is new to you,
(say, dose-ﬁnding) then this book can jump start your transition, but this won’t be
the book that you constantly reach for as you hone your skills.
Statisticians with limited experience in drug development will greatly beneﬁt
from seeing the careful layout of controversies that are unique to this arena. I
especially loved the description of the controversies associated with intention-to-
treat analysis and random effects in a multicenter trial.
Another possible audience is researchers who want to develop a greater
degree of sophistication in their work by better understanding the statistical issues
associated with the design and analysis of drug development studies. You may want
this book, just to help answer questions from some of your more sophisticated
clients. To help some of the math-phobic clients, Dr. Senn segregates most formulas
to an appendix at the end of the chapter.
It won’t help, though, for your unsophisticated clients. This is not a Statistics
for Idiots book. Even with the mathematics removed, the intellectual caliber required
to appreciate this book is still substantial.
If you own the ﬁrst edition of the book should you buy the second? An entirely
new chapter on pharmacogenomics is nice, but not worth the extra money all by
itself. A better justiﬁcation is that the controversies discussed in the ﬁrst edition have
in most cases heated up rather than settled down. You can’t pretend you’re on top
of these issues with a book that is a decade old. The bibliographies at the end of
each chapter reﬂect this. Of the 953 total references, 634 are new to this edition and
the three quartiles of publication year for these new references are 1995, 2000, and
2004.
Writing a review of this book reminds me of the Will Rogers quote “We can’t
all be heroes, because somebody has to sit on the curb and clap as they go by.” This
book is an outstanding effort from a statistician of heroic proportions. Someone
like me is only capable of sitting on the curb and applauding wildly.BOOK REVIEW 219
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